News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
News Protocol violations gut Pfizer’s Lyme disease shot study 50% of US patients in the VALOR study of VLA15 will be discontinued from the trial.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
Digital Connecting patients to treatment on the COVID Care Journey Ada Health and Pfizer have collaborated to launch US nationwide digital COVID-19 Care Journey
News After COVID excess, Pfizer bracing for a hangover in 2023 Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in
News UK digital health funding should be ringfenced, says report IT industry group techUK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
